Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.49 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445507 | 0.86 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ALOX5PTGES | |
| SCHEMBL6344125 | 0.85 | CYP2A6 (0.51) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| SCHEMBL2396391 | 0.84 | CYP2A6 (0.54) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL6237737 | 0.84 | CYP2A6 (0.50) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| SCHEMBL6237741 | 0.82 | CYP2A6 (0.49) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| SCHEMBL9542499 | 0.82 | AGXT (0.52) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| SCHEMBL1444257 | 0.79 | CYP2A6 (0.45) | CYP2A6ASIC3LOXL2ALOX5AGXT | |
| SCHEMBL1444702 | 0.79 | CYP2A6 (0.45) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| Tetrylammonium SCHEMBL6237150 | 0.78 | CYP2A6 (0.44) | CYP2A6ASIC3LOXL2ALOX5CYP1A2 | |
| SCHEMBL4847281 | 0.77 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782448-B2 | Methods and compositions for treating skin | ELC MANAGEMENT LLC (US) | 2017-10-10 | — | — | US | claimed |
| US-20140161898-A1 | Methods and Compositions for Treating Skin | ELC MANAGEMENT, LLC (US) | 2014-06-12 | — | — | US | claimed |
| US-8535738-B2 | Methods and compositions for treating skin | ELC MANAGEMENT, LLC (US) | 2013-09-17 | — | — | US | claimed |
| WO-2010124283-A2 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY (US) | 2010-10-28 | — | — | WO | claimed |
| WO-2010012246-A1 | A PROCESS FOR THE PREPARATION OF N-(1-BENZO[B]THIEN-2-YLETHYL)-N-HYDROXYUREA | FARMAK, A.S. (CZ) | 2010-02-04 | — | — | WO | claimed |
| EP-1954245-A2 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | Baxter International Inc. (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007059515-A2 | COMPOSITIONS OF LIPOXYGENASE INHIBITORS | BAXTER INTERNATIONAL, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-0543855-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-06-02 | — | — | EP | claimed |
| EP-0477289-A4 | ANHYDROUS OIL-BASED LIQUID SUSPENSION FOR DELIVERING A MEDICAMENT | — | 1992-07-22 | — | — | EP | claimed |
| EP-0477289-A1 | ANHYDROUS OIL-BASED LIQUID SUSPENSION FOR DELIVERING A MEDICAMENT | ABBOTT LABORATORIES (US) | 1992-04-01 | — | — | EP | claimed |
| WO-1992003130-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-05 | — | — | WO | claimed |
| WO-1991008734-A1 | ANHYDROUS OIL-BASED LIQUID SUSPENSION FOR DELIVERING A MEDICAMENT | ABBOTT LABORATORIES (US) | 1991-06-27 | — | — | WO | claimed |
| WO-2024044654-A2 | PARENTERAL COMPOSITIONS OF ZILEUTON AND METHODS OF USE | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20210369669-A1 | AUTOPHAGY ACTIVATORS AND INHIBITORS OF FERROPTOSIS FOR PREVENTING ACUTE RENAL FAILURE AND NEUROTOXCITY INDUCED BY CERTAIN ANTIBIOTICS | SYSTAMEDIC INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3849588-A1 | COVERSIN FOR USE IN THE TREATMENT OF RHEUMATIC DISEASES | Volution Immuno Pharmaceuticals SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3292117-B1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | HOFFMANN LA ROCHE (CH) | 2020-08-12 | — | — | EP | disclosed |
| WO-1992003130-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| WO-1991008734-A1 | ANHYDROUS OIL-BASED LIQUID SUSPENSION FOR DELIVERING A MEDICAMENT | ABBOTT LABORATORIES (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0416609-A2 | Benzo[b]thiophene-containing lipoxygenase-inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161898-A1 | Methods and Compositions for Treating Skin | LTB4R2, LTB4R, CYSLTR2 | CYP2A6 2601/4885ASIC3 1017/4885LOXL2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.